Arvinas, Inc. (ARVN)
NASDAQ: ARVN · Real-Time Price · USD
13.60
-0.12 (-0.87%)
At close: Mar 6, 2026, 4:00 PM EST
14.05
+0.45 (3.31%)
After-hours: Mar 6, 2026, 5:59 PM EST
Arvinas Revenue
In the year 2025, Arvinas had annual revenue of $262.60M, down -0.30%. Arvinas had revenue of $9.50M in the quarter ending December 31, 2025, a decrease of -83.95%.
Revenue (ttm)
$262.60M
Revenue Growth
-0.30%
P/S Ratio
3.31
Revenue / Employee
$1,067,480
Employees
246
Market Cap
869.87M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 262.60M | -800.00K | -0.30% |
| Dec 31, 2024 | 263.40M | 184.90M | 235.54% |
| Dec 31, 2023 | 78.50M | -52.90M | -40.26% |
| Dec 31, 2022 | 131.40M | 77.80M | 145.15% |
| Dec 31, 2021 | 53.60M | 27.70M | 106.95% |
| Dec 31, 2020 | 25.90M | -17.10M | -39.77% |
| Dec 31, 2019 | 43.00M | 28.68M | 200.20% |
| Dec 31, 2018 | 14.32M | 6.75M | 89.00% |
| Dec 31, 2017 | 7.58M | 909.85K | 13.64% |
| Dec 31, 2016 | 6.67M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Fortrea Holdings | 2.72B |
| Phathom Pharmaceuticals | 175.11M |
| ARS Pharmaceuticals | 142.77M |
| Xencor | 125.58M |
| uniQure | 16.10M |
| Arbutus Biopharma | 14.61M |
| Evommune | 13.00M |
| Janux Therapeutics | 10.00M |
ARVN News
- 10 days ago - Arvinas, Inc. (ARVN) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 10 days ago - Arvinas Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 11 days ago - Arvinas to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 17 days ago - Arvinas to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026 - GlobeNewsWire
- 22 days ago - Arvinas Announces Appointment of Randy Teel, Ph.D., as President, Chief Executive Officer, and Director - GlobeNewsWire
- 3 months ago - Arvinas Presents Preclinical Data Supporting Mechanistic Synergies and Enhanced Antitumor Activity with the Combination of ARV-393 and Glofitamab at the 2025 American Society of Hematology Annual Meeting and Exposition - GlobeNewsWire
- 3 months ago - Arvinas to Present at Piper Sandler 37th Annual Healthcare Conference - GlobeNewsWire
- 3 months ago - Arvinas Announces Data Presentations from the Vepdegestrant (ARV-471) Clinical Development Program at the 2025 San Antonio Breast Cancer Symposium (SABCS) - GlobeNewsWire